Product Review: Topical Methylprednisolone Aceponate for eczema

In this review:

This review discusses the evidence in support of the use of methylprednisolone aceponate (MPA) 0.1% ointment/cream [Advantan®], a fourth-generation, non-halogenated topical corticosteroid approved for use in New Zealand for the management of eczema. MPA exhibits a fast and effective itch relief profile in infants and children with atopic eczema. MPA has the advantage of once-daily dosing, providing benefits in terms of patient compliance, and has an optimised efficacy/safety profile with minimal local or systemic adverse effects. This agent is suitable for use in adults and children and also for short-term use on the face. The choice of 2 topical MPA formulations allows tailored treatment for a variety of eczema types and locations. MPA 0.1% ointment/cream is fully funded. This review is sponsored by an educational grant from Leo Pharma Limited.

Please login below to download this issue (PDF)